BriaCell to Present Bria-OTS+(TM) Preclinical Data at SITC 2025 Annual Meeting

Stock Information for BriaCell Therapeutics Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About BriaCell Therapeutics Corp.

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+(TM) at SITC 2025
BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+(TM) in Breast and Prostate Cancer Models
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study
BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+(TM) for Breast Cancer
BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025
BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025
BriaCell's Bria-OTS+(TM) Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.